Nov 08, 2024 / 01:00PM GMT
Operator
Thank you and welcome everybody to the kiss. We cost and also the business updates that we can provide at this point in time as a summary of Q3 and also some of the significant events that we reported after the reporting date, we have opened the first clinical centers for the AM LM 22 cadence trial. This is a trial run by the Osas Leukemia and Lymphoma Group. And they opened up the first centers in Australia which we also communicated via LinkedIn yesterday. But we're happy that the trial is finally open for recruitment.
We have worked with no X our manufacturer with whom we have a manufacturing alliance for implementation of the large-scale manufacturing of our lead product. Vs, it's a crucial part of our preparations for pivotal stage readiness. And we're happy to report that the alliance is on track.
The collaboration we announced in July with Insig Bonni allows us to reenter into the clinic. Our second clinical stage product ELIXA Ensel and we will study this program in soft tissue sarcomas will provide more background of that indication. And the trial during the call, we will have a
Q3 2024 Mendus AB (publ) Earnings Call Transcript
4 days ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers